<SEC-DOCUMENT>0001213900-25-105632.txt : 20251104
<SEC-HEADER>0001213900-25-105632.hdr.sgml : 20251104
<ACCEPTANCE-DATETIME>20251104081531
ACCESSION NUMBER:		0001213900-25-105632
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		7
CONFORMED PERIOD OF REPORT:	20251104
FILED AS OF DATE:		20251104
DATE AS OF CHANGE:		20251104

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ASCENTAGE PHARMA GROUP INTERNATIONAL
		CENTRAL INDEX KEY:			0002023311
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			E9
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-42484
		FILM NUMBER:		251446550

	BUSINESS ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		68 XINQING ROAD
		STREET 2:		SUZHOU INDUSTRIAL PARK
		CITY:			SUZHOU , JIANGSU
		PROVINCE COUNTRY:   	F4
		BUSINESS PHONE:		86 512 8555 7777

	MAIL ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		68 XINQING ROAD
		STREET 2:		SUZHOU INDUSTRIAL PARK
		CITY:			SUZHOU , JIANGSU
		PROVINCE COUNTRY:   	F4
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ea0263824-6k_ascentage.htm
<DESCRIPTION>REPORT OF FOREIGN PRIVATE ISSUER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Washington,
D.C. 20549 </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Form
6-K </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Report of Foreign Private Issuer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Pursuant to Rule 13a-16 or 15d-16</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>under the Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">For the month of <B>November 2025</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Commission File Number: 001-42484</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>ASCENTAGE PHARMA GROUP INTERNATIONAL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>(Translation of Registrant&rsquo;s name into
English)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>68 Xinqing Road</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Suzhou Industrial Park</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Suzhou, Jiangsu</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>China</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Address of principal executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Form 20-F &#9746; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form
40-F &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On November 3, 2025, Ascentage Pharma Group International (&ldquo;Ascentage
Pharma&rdquo; or the &ldquo;Company&rdquo;) issued two press releases entitled, &ldquo;Ascentage Pharma to Present Data from Multiple
Studies of Olverembatinib, Including the First Dataset from POLARIS-1 Study, at ASH 2025&rdquo; and &ldquo;Ascentage Pharma to Present
Data from Two Clinical Studies for Bcl-2 Inhibitor Lisaftoclax, Including an Oral Report, at ASH 2025&rdquo;. A copy of the press releases
are furnished as Exhibits 99.1 and 99.2 to this Report. On November 4, 2025, Ascentage Pharma Group International posted an announcement
on the Hong Kong Stock Exchange entitled, &ldquo;Ascentage Pharma to Present Results from Multiple Clinical Studies of olverembatinib,
lisaftoclax, APG-5918 at the 2025 American Society of Hematology (ASH) Annual Meeting, one of which have been selected for Oral Reports&rdquo;.
A copy of the announcement is furnished as Exhibit 99.3 to this Report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>INDEX TO EXHIBITS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="border-bottom: black 1.5pt solid; vertical-align: top; width: 9%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit<BR>
Number</B></FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 90%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit Title</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ea026382401ex99-1_ascentage.htm">Press release dated November 3, 2025</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.2</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ea026382401ex99-2_ascentage.htm">Press release date November 3, 2025</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.3</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="ea026382401ex99-3_ascentage.htm">Announcement dated November 4, 2025</A></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SIGNATURE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ASCENTAGE PHARMA GROUP INTERNATIONAL</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: November 4, 2025</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ Dajun Yang</I></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: </FONT></TD>
    <TD STYLE="text-align: left; width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dajun Yang</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea026382401ex99-1_ascentage.htm
<DESCRIPTION>PRESS RELEASE DATED NOVEMBER 3, 2025
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="ex99-1_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Ascentage Pharma to Present Data from Two Clinical
Studies for Bcl-2 Inhibitor Lisaftoclax, Including an Oral Report, at ASH 2025</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>ROCKVILLE, Md. and SUZHOU, China, November
3, 2025</B> &mdash; Ascentage Pharma Group International Inc. (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical
company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs
in cancer, announced that the latest results from two clinical studies of its novel drug, lisaftoclax (APG-2575), have been selected for
presentations, including an oral report, at the 67th American Society of Hematology (ASH) Annual Meeting. This is the fourth consecutive
year in which clinical results on lisaftoclax have been selected by the ASH Annual Meeting. This year, data from multiple clinical and
preclinical studies on three of the company&rsquo;s investigational drug candidates (lisaftoclax, olverembatinib, and APG-5918) have been
selected for presentations at the ASH Annual Meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Developed by Ascentage Pharma, lisaftoclax is
an orally available Bcl-2 inhibitor. Early data from the studies have demonstrated effects on hematologic malignancies and solid tumors.
Lisaftoclax is being commercialized in China following National Medical Products Administration (NMPA) approval for the treatment of adult
patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have previously received at least one systemic therapy
including Bruton&rsquo;s tyrosine kinase (BTK) inhibitors. At this year&rsquo;s ASH Annual Meeting, Ascentage Pharma will present an oral
report featuring the latest results from a registrational Phase II study of lisaftoclax monotherapy in patients with relapsed/refractory
(R/R) CLL/SLL. Moreover, Ascentage Pharma will present a poster featuring the latest data of lisaftoclax in combination with azacitidine
(AZA) in patients with newly diagnosed (ND) or prior venetoclax&ndash;exposed myeloid malignancies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The ASH Annual Meeting is one of the largest gatherings
of the international hematology community, aggregating the latest scientific research on the pathogenesis and clinical treatment of hematologic
diseases. The 67th ASH Annual Meeting will take place on December 6-9, 2025, local time, both online and in-person in Orlando, Florida.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Dr. Yifan Zhai, Chief Medical Officer of Ascentage
Pharma</B>, said, &ldquo;Lisaftoclax has demonstrated efficacy and manageable safety profiles across numerous studies to-date. Lisaftoclax
is currently being evaluated in four global registrational Phase III studies. At ASH 2025, the latest clinical data supporting lisaftoclax
were once again selected for presentations, including an oral report, underscoring the drug&rsquo;s therapeutic potential in hematologic
diseases. We are pleased that multiple studies of our key drug candidates have been selected for presentation at the ASH Annual Meeting,
demonstrating Ascentage Pharma&rsquo;s robust capabilities in global innovation and clinical development. We are eager to share more detailed
results during the conference and will continue to accelerate our clinical development programs in order to bring more treatment options
to patients as soon as possible.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">An overview of presentations featuring Ascentage
Pharma&rsquo;s drug candidates at ASH 2025:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 17%; padding-right: 5.4pt; padding-left: 5.4pt"><B>Format</B> <B>&nbsp;</B></TD>
    <TD STYLE="text-align: center; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 21%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: middle"><B>Drug <BR>
Candidate</B> <B>&nbsp;</B></TD>
    <TD STYLE="padding-bottom: 2pt; text-align: center; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 48%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: middle"><B>Abstract Title</B> <B>&nbsp;</B></TD>
    <TD STYLE="text-align: center; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 14%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: middle"><B>Abstract#</B> <B>&nbsp;</B></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-right: 5.4pt; padding-left: 0.25in">Oral
    Presentation &nbsp;</TD>
    <TD STYLE="text-align: center; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-right: 5.4pt; padding-left: 0.25in; vertical-align: middle">Lisaftoclax <BR>
&#65288;APG-2575&#65289;</TD>
    <TD STYLE="padding-bottom: 2pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt">Results of a registrational phase 2 study of lisaftoclax monotherapy for treatment of patients (pts) with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who had failed Bruton&rsquo;s tyrosine kinase inhibitors (BTKis) &nbsp;</TD>
    <TD STYLE="vertical-align: middle; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">88</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD ROWSPAN="9" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-right: 5.4pt; padding-left: 0.25in">Poster
    Presentation &nbsp;</TD>
    <TD STYLE="text-align: center; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-right: 5.4pt; padding-left: 0.25in; vertical-align: middle">Lisaftoclax <BR>
&#65288;APG-2575&#65289;</TD>
    <TD STYLE="padding-bottom: 2pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt">Results of the APG2575AU101 study of lisaftoclax (APG-2575) combined with azacitidine (AZA) in patients with newly diagnosed (ND) or prior venetoclax&ndash;exposed myeloid malignancies &nbsp;</TD>
    <TD STYLE="vertical-align: middle; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">1641</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD ROWSPAN="7" STYLE="text-align: center; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-right: 5.4pt; padding-left: 0.25in; vertical-align: middle">Olverembatinib <BR>
&#65288;HQP1351&#65289;</TD>
    <TD STYLE="padding-bottom: 2pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt">Results of POLARIS-1, a global phase 3 study (Part A): olverembatinib combined with low-intensity chemotherapy in patients with newly diagnosed (ND) Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) &nbsp;</TD>
    <TD STYLE="vertical-align: middle; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">1574</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-bottom: 2pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt">Olverembatinib (HQP1351) demonstrates efficacy vs. best available therapy (BAT) in patients (pts) with tyrosine kinase inhibitor (TKI)-resistant chronic-phase chronic myeloid leukemia (CML-CP) in a registrational randomized phase 2 trial: up to 4-year follow-up including patients without T315I mutations &nbsp;</TD>
    <TD STYLE="vertical-align: middle; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">3788</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-bottom: 2pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt">Updated efficacy and safety of olverembatinib (HQP1351) as second-line therapy in patients with chronic phase-chronic myeloid leukemia (CP-CML) &nbsp;</TD>
    <TD STYLE="vertical-align: middle; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">3782</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-bottom: 2pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt">Preclinical and clinical Study of olverembatinib in patients with myeloid/lymphoid neoplasms with FGFR1 rearrangement &nbsp;</TD>
    <TD STYLE="vertical-align: middle; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">1979</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-bottom: 2pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt">Olverembatinib-mediated deep remission improves allogeneic stem cell transplantation outcome in patients with blast crisis chronic myeloid leukemia: First real-world practice report &nbsp;</TD>
    <TD STYLE="vertical-align: middle; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">1999</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-bottom: 2pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt">The efficacy and safety of switching to olverembatinib or continuing original TKI therapy in CML-CP patients treated with at least two prior TKIs: A prospective, multicenter, control trial &nbsp;</TD>
    <TD STYLE="vertical-align: middle; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">3779</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-bottom: 2pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt">Clinical and molecular features associated with glucolipid metabolic disorders and cardio-/cerebro-vascular adverse events in CML patients receiving olverembatinib therapy </TD>
    <TD STYLE="vertical-align: middle; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">5561</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: middle; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 0.125in; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">APG-5918</FONT></TD>
    <TD STYLE="padding-bottom: 2pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt">Embryonic ectoderm development (EED) inhibitor APG-5918 overcomes immunomodulatory drug (IMiD) resistance as monotherapy and synergizes with IMiDs/cereblon E3 ligase modulators (CELMoDs) in preclinical models of multiple myeloma (MM) &nbsp;</TD>
    <TD STYLE="vertical-align: middle; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">1528</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD ROWSPAN="2" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-right: 5.4pt; padding-left: 0.25in">Abstract
    Only &nbsp;</TD>
    <TD STYLE="text-align: center; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-right: 5.4pt; padding-left: 0.25in; vertical-align: middle">Olverembatinib <BR>
&#65288;HQP1351&#65289;</TD>
    <TD STYLE="padding-bottom: 2pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt">Single CAR-t infusion during front-line consolidation induces deep and sustained remission in newly diagnosed adult ph+b- ALL: A prospective phase 2 study &nbsp;</TD>
    <TD STYLE="vertical-align: middle; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">442</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-right: 5.4pt; padding-left: 0.25in; vertical-align: middle">Lisaftoclax <BR>
&#65288;APG-2575&#65289;</TD>
    <TD STYLE="padding-bottom: 2pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt">BCL-2 inhibition in North American adult T-cell leukemia/lymphoma: Preclinical insights and early clinical outcomes &nbsp;</TD>
    <TD STYLE="vertical-align: middle; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">3304</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Study abstracts on lisaftoclax selected for presentations
at the 2025 ASH Annual Meeting are as follows: (for details on the abstracts featuring olverembatinib, please refer to a separate press
release published at the same time)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Oral Presentation</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Results of a registrational phase 2 study of
lisaftoclax monotherapy for treatment of patients (pts) with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma
(CLL/SLL) who had failed Bruton&rsquo;s tyrosine kinase inhibitors (BTKis)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Format:</B> Oral Presentation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Abstract#:</B> 88</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Session:</B> 642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological:
Treatment of CLL in Relapse and in Richter Transformation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Time:</B> Saturday, December 6, 2025; 10:15 AM - 10:30 AM EST</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>First Author: </B>Prof. Keshu Zhou, The Affiliated Cancer Hospital
of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Presenter:</B> Prof. Keshu Zhou, The Affiliated Cancer Hospital
of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Highlights:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This is a pivotal registrational Phase II study (NCT05147467) in patients
with CLL/SLL, with the objective response rate (ORR) as its primary endpoint. Patients in this study were refractory to, relapsed on,
or intolerant of both BTK inhibitors and immunochemotherapy; or failed prior BTK inhibitors and were ineligible for immunochemotherapy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Efficacy
Results</U>: As of July 25, 2025, among 72 evaluable patients with R/R CLL/SLL, the ORR as confirmed by the independent review
committee (IRC) was 62.5%, the median
progression-free survival (mPFS) was 23.89 months (with a median follow-up of 22.01 months). Among high-risk patients (those with
adverse prognostic genotypes such as del(17p)/<I>TP53</I> mutation, chromosomal complex karyotype, and unmutated <I>IGHV</I>), the
treatment showed clinically meaningful deep responses. 21.8% of patients achieved minimal residual disease (MRD) negativity in
peripheral blood. In the 11 evaluable patients with bone marrow MRD, 6 achieved MRD-negativity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Safety Results</U>: Lisaftoclax demonstrated a manageable safety
profile in BTKi-pretreated patients. Frequent grade &ge;3 treatment-related adverse events were hematologic toxicities that included decreased
neutrophil, decreased platelet count, and anemia. No tumor-lysis syndrome (TLS) was reported and no treatment-related deaths occurred
during the study.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Conclusion</U>: Lisaftoclax monotherapy demonstrated significant
and durable clinical efficacy and a manageable safety profile in patients with heavily-pretreated BTK-refractory R/R CLL/SLL, underscoring
its utility as a potential new treatment option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Poster Presentation:</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Results of the APG2575AU101 study of lisaftoclax
(APG-2575) combined with azacitidine (AZA) in patients with newly diagnosed (ND) or prior venetoclax&ndash;exposed myeloid malignancies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Format:</B> Poster Presentation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Abstract#:</B> 1641</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Session:</B> 616. Acute Myeloid Leukemias: Investigational Drug
and Cellular Therapies: Poster I</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Time:</B> Saturday, December 6, 2025; 5:30 PM &ndash; 7:30 PM EST</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>First Author:</B> Dr. Tapan Kadia, Department of Leukemia, The University
of Texas MD Anderson Cancer Center</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Presenter:</B> Dr. Tapan Kadia, Department of Leukemia, The University
of Texas MD Anderson Cancer Center</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Highlights:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">This is a phase I/II study (NCT04964518) designed to evaluate the safe dose
and efficacy of lisaftoclax in combination with AZA in patients with ND or R/R acute myeloid leukemia (AML), mixed-phenotype acute leukemia
(MPAL), chronic myelomonocytic leukemia (CMML), or higher-risk (HR) myelodysplastic syndromes (MDS). The first part of this study is the
dose-escalation phase and the second part is the dose-expansion phase.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">As of July 1, 2025, a total 103 patients were enrolled, including 63 patients
with AML/MPAL (of whom 56 patients had relapsed/refractory diseases) and 40 patients with HR MDS/CMML (of whom 25 patients had relapsed/refractory
diseases).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Efficacy Results as of July 1, 2025</U>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">In the 47 evaluable patients with R/R AML/MPAL, the ORR was 40.4%, the complete
response (CR) rate was 29.8% (14/47). In the 24 patients with venetoclax&ndash;exposed R/R AML/MPAL, the ORR was 29.2% (7/24), the CR
rate was 20.8% (5/24).</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">In the 15 evaluable patients with ND HR MDS/CMML, the ORR was 80.0%, including
6 (40.0%) patients who achieved a CR, and 6 (40.0%) who achieved a marrow CR (mCR).</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Median overall survival (OS) values for patients with R/R AML/MPAL or R/R
HR MDS/CMML were 7.6 months and 11.3 months, respectively.</FONT></TD></TR>
                                                                           </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">The median OS of patients with ND AML/MPAL was 6.3 months and it was not
reached in patients with ND HR MDS/CMML.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Safety Results</U>: No dose-limiting toxicities (DLTs) were reported
in part one for dose-escalation or part two for dose-expansion. Common grade &ge;3 treatment-emergent adverse events (TEAEs) included
neutropenia (41.7%), febrile neutropenia (35.0%), thrombocytopenia (26.2%), anemia (17.5%).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Conclusion</U>: These preliminary clinical data show that the combination
regimen of lisaftoclax plus AZA holds promise in overcoming venetoclax resistance, therefore potentially offering a new treatment option
to patients with AML/HR MDS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><I>*</I></TD><TD STYLE="text-align: justify"><I>Olverembatinib, lisaftoclax and APG-5918 are currently under
investigation and have not yet been approved by the FDA in the US.</I></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Ascentage Pharma</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (&ldquo;Ascentage
Pharma&rdquo; or the &ldquo;Company&rdquo;) is a global, commercial stage, integrated biopharmaceutical company engaged in the discovery,
development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer. The Company has built a
rich pipeline of innovative drug products and candidates that includes inhibitors targeting key proteins in the apoptotic pathway, such
as Bcl-2 and MDM2-p53, as well as next-generation kinase inhibitors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The lead asset, olverembatinib, is the first novel third-generation
BCR-ABL1 inhibitor approved in China for the treatment of patients with CML in chronic phase (CML-CP) with T315I mutations, CML in accelerated
phase (CML-AP) with T315I mutations, and CML-CP that is resistant or intolerant to first and second-generation TKIs. All indications are
covered by the China National Reimbursement Drug List (NRDL). The Company is currently conducting an FDA-cleared, global registrational
Phase III trial, or POLARIS-2, of olverembatinib for CML, as well as global registrational Phase III trials for patients with newly diagnosed
Ph+ ALL and SDH-deficient GIST patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">The Company</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s
second approved product, lisaftoclax, is a novel Bcl-2 inhibitor for the treatment of various hematologic malignancies. Lisaftoclax is
being commercialized in China following National Medical Products Administration (NMPA) approval for the treatment of adult patients with
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have previously received at least one systemic therapy including
Bruton</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s tyrosine kinase (BTK) inhibitors. The Company is currently
conducting four global registrational Phase III trials: the FDA-cleared GLORA study of lisaftoclax in combination with BTK inhibitors
in patients with CLL/SLL previously treated with BTK inhibitors for more than 12 months with suboptimal response; the GLORA-2 study in
patients with newly diagnosed CLL/SLL; the GLORA-3 study in newly diagnosed, elderly and unfit patients with acute myeloid leukemia (
AML); and the GLORA-4 study in patients with newly diagnosed higher-risk myelodysplastic syndrome (HR MDS), a study that was simultaneously
cleared by the US FDA, the EMA of the EU, and China CDE.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Leveraging its robust R&amp;D capabilities, Ascentage Pharma has built
a portfolio of global intellectual property rights and entered into global partnerships and other relationships with numerous leading
biotechnology and pharmaceutical companies, such as Takeda, AstraZeneca, Merck, Pfizer, and Innovent, in addition to research and development
relationships with leading research institutions, such as Dana-Farber Cancer Institute, Mayo Clinic, National Cancer Institute and the
University of Michigan. For more information, visit https://ascentage.com/</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This press release includes forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, contained in this press release
may be forward-looking statements, including statements that express Ascentage Pharma&rsquo;s opinions, expectations, beliefs, plans,
objectives, assumptions or projections regarding future events or future results of operations or financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">These forward-looking statements are subject to a number of risks and
uncertainties as discussed in Ascentage Pharma&rsquo;s filings with the SEC, including those set forth in the sections titled &ldquo;Risk
factors&rdquo; and &ldquo;Special note regarding forward-looking statements and industry data&rdquo; in its Registration Statement on
Form F-1, as amended, filed with the SEC on January 21, 2025, and the Form 20-F filed with the SEC on April 16, 2025, the sections headed
&ldquo;Forward-looking Statements&rdquo; and &ldquo;Risk Factors&rdquo; in the prospectus of the Company for its Hong Kong initial public
offering dated October 16, 2019, and other filings with the SEC and/or The Stock Exchange of Hong Kong Limited we made or make from time
to time that may cause actual results, levels of activity, performance or achievements to be materially different from the information
expressed or implied by these forward-looking statements. The forward-looking statements contained in this presentation do not constitute
profit forecast by the Company&rsquo;s management.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As a result of these factors, you should not rely on these forward-looking
statements as predictions of future events. The forward-looking statements contained in this press release are based on Ascentage Pharma&rsquo;s
current expectations and beliefs concerning future developments and their potential effects and speak only as of the date of such statements.
Ascentage Pharma does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information,
future events or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Contacts</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Investor Relations:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Hogan Wan, Head of IR and Strategy</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ascentage Pharma</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Hogan.Wan@ascentage.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">+86 512 85557777</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Stephanie Carrington</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ICR Healthcare</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">AscentageIR@icrhealthcare.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">+1 (646) 277-1282</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Media Relations:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Jon Yu</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ICR Healthcare</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">AscentagePR@icrhealthcare.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">+1 (646) 677-1855</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>ea026382401ex99-2_ascentage.htm
<DESCRIPTION>PRESS RELEASE DATE NOVEMBER 3, 2025
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="ex99-2_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Ascentage Pharma to Present Data from Multiple
Studies of Olverembatinib, Including the First Dataset from POLARIS-1 Study, at ASH 2025</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>ROCKVILLE, Md. and SUZHOU, China, November
3, 2025</B> &mdash; Ascentage Pharma Group International Inc. (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical
company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs
in cancer, announced that the latest results from multiple clinical studies of its novel drug, olverembatinib (HQP1351), have been selected
for presentations at the 67th American Society of Hematology (ASH) Annual Meeting, marking the eighth consecutive year in which clinical
data on olverembatinib have been selected by ASH for the Annual Meeting. This year, multiple clinical and preclinical studies on three
of the company&rsquo;s investigational drug candidates (olverembatinib, lisaftoclax and APG-5918) have been selected for presentations
at the ASH Annual Meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Developed by Ascentage Pharma, olverembatinib
is the first China-approved third-generation BCR-ABL inhibitor, currently being jointly commercialized in China by Ascentage Pharma and
Innovent Biologics. At this year&rsquo;s ASH Annual Meeting, Ascentage Pharma will release the first dataset from the global Phase III
study (POLARIS-1) of olverembatinib combined with low-intensity chemotherapy in patients with newly diagnosed (ND) Philadelphia chromosome-positive
(Ph+) acute lymphoblastic leukemia (ALL). Moreover, 4-year follow-up data from a randomized controlled, registrational Phase II study
of olverembatinib in patients with tyrosine kinase inhibitor (TKI)-resistant chronic-phase chronic myeloid leukemia (CML-CP); and updated
data on olverembatinib in the second-line treatment of patients with non-T315I-mutant CML-CP are also set to be reported at the ASH Annual
Meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The ASH Annual Meeting is one of the largest gatherings
of the international hematology community, aggregating the latest scientific research on the pathogenesis and clinical treatment of hematologic
diseases. The 67th ASH Annual Meeting will take place on December 6-9, 2025, local time, both online and in-person in Orlando, Florida.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Dr. Yifan Zhai, Chief Medical Officer of Ascentage
Pharma</B>, said, &ldquo;For eight years in a row, clinical data on olverembatinib have been selected by the ASH Annual Meeting, an achievement
reflecting the strong recognition of olverembatinib by the international hematology community. Olverembatinib is currently being evaluated
in three global registrational Phase III studies. This year, multiple studies of our three key drug candidates have been selected for
presentation at the ASH annual Meeting, underscoring Ascentage Pharma&rsquo;s robust capabilities in global innovation and clinical development.
We look forward to sharing more detailed data during the conference. Moving forward, we will continue to accelerate our clinical development
programs in efforts to bring more treatment options to patients as soon as possible.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">An overview of presentations featuring Ascentage
Pharma&rsquo;s drug candidates at ASH 2025:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-left: 5.4pt; border: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 17%; padding-right: 5.4pt"><B>Format</B> <B>&nbsp;</B></TD>
    <TD STYLE="border-top: Black 1pt solid; text-align: center; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 21%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: middle"><B>Drug <BR>
Candidate</B> <B>&nbsp;</B></TD>
    <TD STYLE="padding-bottom: 2pt; text-align: center; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 48%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: middle"><B>Abstract Title</B> <B>&nbsp;</B></TD>
    <TD STYLE="border-top: Black 1pt solid; text-align: center; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 14%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: middle"><B>Abstract#</B> <B>&nbsp;</B></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-left: 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt">Oral
    Presentation </TD>
    <TD STYLE="text-align: center; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-right: 5.4pt; padding-left: 0.25in; vertical-align: middle">Lisaftoclax <BR>
&#65288;APG-2575&#65289;</TD>
    <TD STYLE="padding-bottom: 2pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt">Results of a registrational phase 2 study of lisaftoclax monotherapy for treatment of patients (pts) with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who had failed Bruton&rsquo;s tyrosine kinase inhibitors (BTKis) &nbsp;</TD>
    <TD STYLE="vertical-align: middle; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">88</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD ROWSPAN="9" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.25in; padding-right: 5.4pt">Poster<BR>

    Presentation </TD>
    <TD STYLE="text-align: center; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-right: 5.4pt; padding-left: 0.25in; vertical-align: middle">Lisaftoclax <BR>
&#65288;APG-2575&#65289;</TD>
    <TD STYLE="padding-bottom: 2pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt">Results of the APG2575AU101 study of lisaftoclax (APG-2575) combined with azacitidine (AZA) in patients with newly diagnosed (ND) or prior venetoclax&ndash;exposed myeloid malignancies &nbsp;</TD>
    <TD STYLE="vertical-align: middle; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">1641</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD ROWSPAN="7" STYLE="text-align: center; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-right: 5.4pt; padding-left: 0.25in; vertical-align: middle">Olverembatinib <BR>
&#65288;HQP1351&#65289;</TD>
    <TD STYLE="padding-bottom: 2pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt">Results of POLARIS-1, a global phase 3 study (Part A): olverembatinib combined with low-intensity chemotherapy in patients with newly diagnosed (ND) Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) &nbsp;</TD>
    <TD STYLE="vertical-align: middle; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">1574</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-bottom: 2pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt">Olverembatinib (HQP1351) demonstrates efficacy vs. best available therapy (BAT) in patients (pts) with tyrosine kinase inhibitor (TKI)-resistant chronic-phase chronic myeloid leukemia (CML-CP) in a registrational randomized phase 2 trial: up to 4-year follow-up including patients without T315I mutations &nbsp;</TD>
    <TD STYLE="vertical-align: middle; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">3788</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-bottom: 2pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt">Updated efficacy and safety of olverembatinib (HQP1351) as second-line therapy in patients with chronic phase-chronic myeloid leukemia (CP-CML) &nbsp;</TD>
    <TD STYLE="vertical-align: middle; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">3782</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-bottom: 2pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt">Preclinical and clinical Study of olverembatinib in patients with myeloid/lymphoid neoplasms with FGFR1 rearrangement &nbsp;</TD>
    <TD STYLE="vertical-align: middle; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">1979</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-bottom: 2pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt">Olverembatinib-mediated deep remission improves allogeneic stem cell transplantation outcome in patients with blast crisis chronic myeloid leukemia: First real-world practice report &nbsp;</TD>
    <TD STYLE="vertical-align: middle; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">1999</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-bottom: 2pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt">The efficacy and safety of switching to olverembatinib or continuing original TKI therapy in CML-CP patients treated with at least two prior TKIs: A prospective, multicenter, control trial &nbsp;</TD>
    <TD STYLE="vertical-align: middle; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">3779</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-bottom: 2pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt">Clinical and molecular features associated with glucolipid metabolic disorders and cardio-/cerebro-vascular adverse events in CML patients receiving olverembatinib therapy </TD>
    <TD STYLE="vertical-align: middle; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">5561</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: middle; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 0.125in; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">APG-5918</FONT></TD>
    <TD STYLE="padding-bottom: 2pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt">Embryonic ectoderm development (EED) inhibitor APG-5918 overcomes immunomodulatory drug (IMiD) resistance as monotherapy and synergizes with IMiDs/cereblon E3 ligase modulators (CELMoDs) in preclinical models of multiple myeloma (MM) &nbsp;</TD>
    <TD STYLE="vertical-align: middle; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">1528</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD ROWSPAN="2" STYLE="padding-left: 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt">Abstract
    Only </TD>
    <TD STYLE="text-align: center; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-right: 5.4pt; padding-left: 0.25in; vertical-align: middle">Olverembatinib <BR>
&#65288;HQP1351&#65289;</TD>
    <TD STYLE="padding-bottom: 2pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt">Single CAR-t infusion during front-line consolidation induces deep and sustained remission in newly diagnosed adult ph+b- ALL: A prospective phase 2 study </TD>
    <TD STYLE="vertical-align: middle; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">442</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-right: 5.4pt; padding-left: 0.25in; vertical-align: middle">Lisaftoclax <BR>
&#65288;APG-2575&#65289;</TD>
    <TD STYLE="padding-bottom: 2pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt">BCL-2 inhibition in North American adult T-cell leukemia/lymphoma: Preclinical insights and early clinical outcomes &nbsp;</TD>
    <TD STYLE="vertical-align: middle; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">3304</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Major study abstracts on olverembatinib selected for presentations
at the 2025 ASH Annual Meeting are as follows: (for details on the abstracts featuring lisaftoclax, please refer to a separate press release
published at the same time)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Results of POLARIS-1, a global Phase 3 study (Part A): olverembatinib
combined with low-intensity chemotherapy in patients with newly diagnosed (ND) Philadelphia chromosome-positive (Ph+) acute lymphoblastic
leukemia (ALL)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Format:</B> Poster Presentation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Abstract#:</B> 1574</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Session:</B> 613. Acute Lymphoblastic Leukemias: Therapies Excluding
Allogeneic Transplantation: Poster I</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Time:</B> Saturday, December 6, 2025; 5:30 PM &ndash; 7:30 PM EST</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>First Author:</B> Prof. Suning Chen, Department of Hematology, The
First Affiliated Hospital of Soochow University, Suzhou, China</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Presenter:</B> Prof. Suning Chen, Department of Hematology, The
First Affiliated Hospital of Soochow University, Suzhou, China</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Highlights:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This is a global registrational Phase III study (POLARIS-1; NCT06051409)
designed to evaluate the efficacy and safety of olverembatinib combined with low-intensity chemotherapy in patients with ND Ph<SUP>+</SUP>
ALL. The primary endpoint of the study was minimal residual disease (MRD; BCR-ABL/ABL1 &le; 0.01% by qPCR) negativity rate by the end
of three induction cycles.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Efficacy Results</U>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">As of July 18, 2025, among 53 efficacy-evaluable patients, 50 (94.3%) achieved
a complete remission (CR) or CR with incomplete hematologic recovery by the end of induction therapy. The best MRD negativity and MRD-negative
CR rates were 66.0% and 64.2%, respectively.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">IKZF1<SUP>plus </SUP>(particularly with concurrent BTG1 deletion) is a widely
recognized high-risk factor in B-ALL as it can often cause resistance to chemotherapies and a high propensity to relapse. Among the 10
patients in this study who had this genotype, the molecular response rate at the end of the induction therapy was 90% (9/10).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Safety Results</U>: Olverembatinib in combination with low-dose
chemotherapy was well tolerated. Common (incidence &gt;15%) grade &ge;3 treatment-emergent adverse events (TEAEs) were neutropenia (63.6%),
thrombocytopenia (56.4%), leukopenia (54.5%), anemia (49.1%), pneumonia (30.9%), hypokalemia (20%), and abnormal hepatic function (16.4%).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Conclusion</U>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In patients with ND Ph<SUP>+</SUP> ALL, olverembatinib in combination
with chemotherapy demonstrated an MRD-negative CR rate of 64.2% by the end of the induction therapy and a favorable safety profile.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Olverembatinib (HQP1351) demonstrates efficacy vs. best available
therapy (BAT) in patients (pts) with tyrosine kinase inhibitor (TKI)-resistant chronic-phase chronic myeloid leukemia (CML-CP) in a registrational
randomized phase 2 trial: up to 4-year follow-up including patients without T315I mutations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Format:</B> Poster Presentation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Abstract#:</B> 3788</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Session: </B> 632. Chronic Myeloid Leukemia: Clinical and Epidemiological:
Poster II</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Time: </B>Sunday, December 7, 2025; 06:00 PM - 08:00 PM EST</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>First Author:</B> Prof. Qian Jiang, Peking University Institute
of Hematology, Peking University People&rsquo;s Hospital, Beijing, China</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Presenter: </B>Prof. Qian Jiang, Peking University Institute of
Hematology, Peking University People&rsquo;s Hospital, Beijing, China</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Highlights:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">This is an open-label, randomized controlled, multicenter, pivotal registrational
phase II study (NCT04126681) designed to evaluate the efficacy and safety of olverembatinib in patients with CML-CP resistant and/or intolerant
to first- and second-generation TKIs. This report features an update on the results released in an oral presentation at ASH 2023. As of
January 13, 2025, a total of 144 patients with CML-CP were enrolled in the study, including 105 patients without the T315I mutation.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">In this study, patients were randomized at a 2:1 ratio to the olverembatinib
arm or the control arm with investigators&rsquo; choices of best available treatment (BAT). The primary endpoint is event-free survival
(EFS).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Efficacy Results</U>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">The olverembatinib arm achieved a significantly longer EFS than the BAT arm:
among all patients with CML-CP, the median EFS of the olverembatinib arm and the BAT arm were 21.22 months and 2.86 months (<I>P </I>&lt;
0.001), respectively. Among patients with CML-CP without the T315I mutation, the median EFS of the olverembatinib arm and the BAT arm
were 11.96 months and 3.14 months (<I>P</I> = 0.0159), respectively.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Other efficacy parameters of the olverembatinib arm were significantly better
than those of the BAT arm: among all patients with CML-CP, complete hematologic response (CHR) rates of the olverembatinib arm and the
BAT arm were 85% and 34.8%; the complete cytogenetic response (CCyR) rates were 37.5% and 18.9%; the major molecular response (MMR) rates
were 29.5% and 8.1%, respectively. Among patients with CML-CP without the T315I mutation treated in the olverembatinib arm or the BAT
arm, the CHR rates were 82.1% and 50.0%, the CCyR rates were 25.8% and 20.7%, the MMR rates were 16.1% and 10.3%, respectively.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Safety Results</U>: Both olverembatinib and BAT showed a favorable
safety profile in patients with CML-CP with/without the T315I mutation. Major adverse event were hematologic toxicities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Conclusion</U>: Olverembatinib demonstrated clear therapeutic advantage
over the BAT arm in patients with CML-CP resistant and/or intolerant to first- and second-generation TKIs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Updated efficacy and safety of olverembatinib (HQP1351) as second-line
therapy in patients with chronic phase-chronic myeloid leukemia (CP-CML)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Format:</B> Poster Presentation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Abstract#:</B> 3782</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Session:</B> 632. Chronic Myeloid Leukemia: Clinical and Epidemiological:
Poster II</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Time:</B> Sunday, December 7, 2025; 6:00 PM &ndash; 8:00 PM EST</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>First Author:</B> Prof. Weiming Li, Department of Hematology, Union
Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Presenter:</B> Prof. Weiming Li, Department of Hematology, Union
Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Highlights:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This is an open-label, single-arm, multicenter clinical study (ChiCTR2200061655)
designed to evaluate the efficacy and safety of orally administered olverembatinib at 40 mg every other day (QOD) in patients with CP-CML
resistant/intolerant to one prior line of TKIs (including imatinib, flumatinib, nilotinib, and dasatinib) without the T315I mutation.
As of July 24, 2025, the study has enrolled a total of 47 patients with CP-CML without the T315I mutation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Efficacy Results</U>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">As of July 24, 2025, 39 (83.0%) patients received at least one efficacy evaluation;
36 (76.6%) at least two efficacy evaluations; and 34 (72.3%) at least three efficacy evaluations. Two patients had not yet received their
first efficacy evaluation.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">As of the data cut-off date, 71.8% (28/39) of patients achieved a CCyR and
43.6% (17/39) MMR. CCyR and MMR rates assessed at the end of cycles 6, 9, 12, 15, 18, 21, and 24 were 54.3% and 25.7%, 66.7% and 33.3%,
74.2% and 35.5%, 84.6% and 46.2%, 85.7% and 47.6%, 90.0% and 60.0%, and 89.5% and 57.9%, respectively, suggesting that responses deepened
as treatment persisted.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Among 39 efficacy-evaluable patients, 30 had received second-generation TKIs
in first-line treatment. Of them, 76.7% (23/30) achieved a CCyR and 43.3% (13/30) MMR. Among the 9 patients who were pretreated with imatinib,
55.6% (5/9) achieved a CCyR and 44.4% (4/9) MMR.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22pt; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Safety Results</U>: The median (range) treatment duration was 16.0
(1-18) cycles. A total of 42 (89.4%) patients experienced treatment-related adverse events (TRAEs) of any grade, including 21 (44.7%)
patients who experienced grade &ge;3 TRAEs and 6 (12.8%) patients who experienced serious adverse events (SAEs) related to olverembatinib.
Grade &ge;3 hematologic toxicities included platelet count decreased (42.6%), neutropenia (25.5%), and anemia (8.5%). Olverembatinib-related
SAEs included platelet count decreased (6.4%) and anemia, myelosuppression, and pyrexia (2.1% each). No deaths were reported during the
study.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Conclusion</U>: Olverembatinib may provide a safe and effective
second-line treatment for patients with CP-CML, especially for those with disease that had failed on first-line treatment with second-generation
TKIs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><I>*</I></TD><TD STYLE="text-align: left"><I>Olverembatinib, lisaftoclax and APG-5918 are currently under
investigation and have not yet been approved by the FDA in the US.</I></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Ascentage Pharma</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (&ldquo;Ascentage
Pharma&rdquo; or the &ldquo;Company&rdquo;) is a global, commercial stage, integrated biopharmaceutical company engaged in the discovery,
development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer. The Company has built a
rich pipeline of innovative drug products and candidates that includes inhibitors targeting key proteins in the apoptotic pathway, such
as Bcl-2 and MDM2-p53, as well as next-generation kinase inhibitors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The lead asset, olverembatinib, is the first novel third-generation
BCR-ABL1 inhibitor approved in China for the treatment of patients with CML in chronic phase (CML-CP) with T315I mutations, CML in accelerated
phase (CML-AP) with T315I mutations, and CML-CP that is resistant or intolerant to first and second-generation TKIs. All indications are
covered by the China National Reimbursement Drug List (NRDL). The Company is currently conducting an FDA-cleared, global registrational
Phase III trial, or POLARIS-2, of olverembatinib for CML, as well as global registrational Phase III trials for patients with newly diagnosed
Ph+ ALL and SDH-deficient GIST patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">The Company</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s
second approved product, Lisaftoclax, is a novel Bcl-2 inhibitor for the treatment of various hematologic malignancies. Lisaftoclax is
being commercialized in China following National Medical Products Administration (NMPA) approval for the treatment of adult patients with
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have previously received at least one systemic therapy including
Bruton</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s tyrosine kinase (BTK) inhibitors. The Company is currently
conducting four global registrational Phase III trials: the FDA-cleared GLORA study of lisaftoclax in combination with BTK inhibitors
in patients with CLL/SLL previously treated with BTK inhibitors for more than 12 months with suboptimal response; the GLORA-2 study in
patients with newly diagnosed CLL/SLL; the GLORA-3 study in newly diagnosed, elderly and unfit patients with acute myeloid leukemia (
AML); and the GLORA-4 study in patients with newly diagnosed higher-risk myelodysplastic syndrome (HR MDS), a study that was simultaneously
cleared by the US FDA, the EMA of the EU, and China CDE.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Leveraging its robust R&amp;D capabilities, Ascentage Pharma has built
a portfolio of global intellectual property rights and entered into global partnerships and other relationships with numerous leading
biotechnology and pharmaceutical companies, such as Takeda, AstraZeneca, Merck, Pfizer, and Innovent, in addition to research and development
relationships with leading research institutions, such as Dana-Farber Cancer Institute, Mayo Clinic, National Cancer Institute and the
University of Michigan. For more information, visit https://ascentage.com/</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">This press release includes forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, contained
in this press release may be forward-looking statements, including statements that express Ascentage Pharma&rsquo;s opinions, expectations,
beliefs, plans, objectives, assumptions or projections regarding future events or future results of operations or financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">These forward-looking statements are subject to
a number of risks and uncertainties as discussed in Ascentage Pharma&rsquo;s filings with the SEC, including those set forth in the sections
titled &ldquo;Risk factors&rdquo; and &ldquo;Special note regarding forward-looking statements and industry data&rdquo; in its Registration
Statement on Form F-1, as amended, filed with the SEC on January 21, 2025, and the Form 20-F filed with the SEC on April 16, 2025, the
sections headed &ldquo;Forward-looking Statements&rdquo; and &ldquo;Risk Factors&rdquo; in the prospectus of the Company for its Hong
Kong initial public offering dated October 16, 2019, and other filings with the SEC and/or The Stock Exchange of Hong Kong Limited we
made or make from time to time that may cause actual results, levels of activity, performance or achievements to be materially different
from the information expressed or implied by these forward-looking statements. The forward-looking statements contained in this presentation
do not constitute profit forecast by the Company&rsquo;s management.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">As a result of these factors, you should not rely
on these forward-looking statements as predictions of future events. The forward-looking statements contained in this press release are
based on Ascentage Pharma&rsquo;s current expectations and beliefs concerning future developments and their potential effects and speak
only as of the date of such statements. Ascentage Pharma does not undertake any obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Contacts</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Investor Relations:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Hogan Wan, Head of IR and Strategy</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ascentage Pharma</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Hogan.Wan@ascentage.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">+86 512 85557777</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Stephanie Carrington</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ICR Healthcare</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">AscentageIR@icrhealthcare.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">+1 (646) 277-1282</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Media Relations:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Jon Yu</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ICR Healthcare</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">AscentagePR@icrhealthcare.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">+1 (646) 677-1855</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 7; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.3
<SEQUENCE>4
<FILENAME>ea026382401ex99-3_ascentage.htm
<DESCRIPTION>ANNOUNCEMENT DATED NOVEMBER 4, 2025
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right; text-indent: 0pt"><B>Exhibit 99.3</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt"><I>Hong Kong
Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement,
make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising
from or in reliance upon the whole or any part of the contents of this announcement.</I></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="ex99-3_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">ASCENTAGE PHARMA GROUP INTERNATIONAL</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#20126;&#30427;&#37291;&#34277;&#38598;&#22296;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>(Incorporated in the Cayman Islands with limited
liability)</I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Stock Code: 6855)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>VOLUNTARY ANNOUNCEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Ascentage Pharma to Present
Results from Multiple Clinical Studies of olverembatinib, lisaftoclax, APG-5918</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>at the 2025 American
Society of Hematology (ASH) Annual Meeting, one of which have been selected for Oral Reports</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt; text-align: left">Ascentage Pharma Group International
(the &ldquo;<B>Company</B>&rdquo; or &ldquo;<B>Ascentage Pharma</B>&rdquo;) is pleased to announce that the latest results from multiple
clinical and preclinical studies on three of the Company&rsquo;s investigational drug candidates (olverembatinib, lisaftoclax and APG-5918)
have been selected for presentations, including one oral report, at the 67th American Society of Hematology (ASH) Annual Meeting. The
latest results from multiple clinical studies of its novel drug, olverembatinib (HQP1351), have been selected for presentations at the
67th ASH Annual Meeting, marking the eighth consecutive year in which clinical data on olverembatinib have been selected by ASH for the
Annual Meeting. The latest results from two clinical studies of its novel drug, lisaftoclax (APG-2575), have been selected for presentations,
including an oral report, at the 67th ASH Annual Meeting. This is the fourth consecutive year in which clinical results on lisaftoclax
have been selected by the ASH Annual Meeting.</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt; text-align: left">Developed by Ascentage Pharma, olverembatinib
is the first China-approved third-generation BCR-ABL inhibitor, currently being jointly commercialized in China by Ascentage Pharma and
Innovent Biologics, Inc.. At this year&rsquo;s ASH Annual Meeting, Ascentage Pharma will release the first dataset from the global Phase
III study (POLARIS-1) of olverembatinib combined with low-intensity chemotherapy in patients with newly diagnosed (ND) Philadelphia chromosome-positive
(Ph+) acute lymphoblastic leukemia (ALL). Moreover, 4-year follow-up data from a randomized controlled, registrational Phase II study
of olverembatinib in patients with tyrosine kinase inhibitor (TKI)-resistant chronic-phase chronic myeloid leukemia (CML-CP); and updated
data on olverembatinib in the second-line treatment of patients with non-T315I-mutant CML-CP are also set to be reported at the ASH Annual
Meeting.</P>




<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt; text-align: left">Developed by Ascentage Pharma, lisaftoclax
is an orally available Bcl-2 inhibitor. Early data from the studies have demonstrated effects on hematologic malignancies and solid tumors.
Lisaftoclax is being commercialized in China following National Medical Products Administration (NMPA) approval for the treatment of adult
patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have previously received at least one systemic therapy
including Bruton&rsquo;s tyrosine kinase (BTK) inhibitors. At this year&rsquo;s ASH Annual Meeting, Ascentage Pharma will present an oral
report featuring the latest results from a registrational Phase II study of lisaftoclax monotherapy in patients with relapsed/refractory
(R/R) CLL/SLL. Moreover, Ascentage Pharma will present a poster featuring the latest data of lisaftoclax in combination with azacitidine
(AZA) in patients with newly diagnosed (ND) or prior venetoclax-exposed myeloid malignancies.</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt; text-align: left">The ASH Annual Meeting is one of the
largest gatherings of the international hematology community, aggregating the latest scientific research on the pathogenesis and clinical
treatment of hematologic diseases. The 67th ASH Annual Meeting will take place on December 6 to December 9, 2025, local time, both online
and in-person in Orlando, Florida.</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">An overview of presentations featuring
Ascentage Pharma&rsquo;s drug candidates at ASH 2025 are set out as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border: #231F20 1pt solid; padding-top: 2pt; padding-bottom: 2pt; text-align: center; width: 18%; font-size: 10pt; vertical-align: middle"><FONT STYLE="font-size: 10pt"><B>Format</B></FONT></TD>
    <TD STYLE="padding: 2pt 5.4pt; border-top: #231F20 1pt solid; border-right: #231F20 1pt solid; border-bottom: #231F20 1pt solid; text-align: center; width: 21%; font-size: 10pt; vertical-align: middle"><FONT STYLE="font-size: 10pt"><B>Drug Candidate</B></FONT></TD>
    <TD STYLE="border-top: #231F20 1pt solid; padding: 2pt 5.4pt; border-right: #231F20 1pt solid; border-bottom: #231F20 1pt solid; text-align: center; width: 45%; font-size: 10pt; vertical-align: middle"><FONT STYLE="font-size: 10pt"><B>Abstract Title</B></FONT></TD>
    <TD STYLE="padding: 2pt 5.4pt; border-top: #231F20 1pt solid; border-right: #231F20 1pt solid; border-bottom: #231F20 1pt solid; text-align: center; width: 16%; font-size: 10pt; vertical-align: middle"><FONT STYLE="font-size: 10pt"><B>Abstract <BR>
number</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: #231F20 1pt solid; border-bottom: #231F20 1pt solid; border-left: #231F20 1pt solid; text-align: center; vertical-align: middle">Oral
    Presentation</TD>
    <TD STYLE="text-align: center; border-right: #231F20 1pt solid; border-bottom: #231F20 1pt solid; vertical-align: middle">Lisaftoclax<BR>
 <FONT STYLE="font-family: Times New Roman, Times, Serif">&#65288;</FONT>APG-2575<FONT STYLE="font-family: Times New Roman, Times, Serif">&#65289;</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 2pt; border-right: #231F20 1pt solid; border-bottom: #231F20 1pt solid; padding-left: 5.6pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Results of a registrational phase 2 study of lisaftoclax monotherapy for treatment of patients (pts) with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who had failed Bruton&rsquo;s tyrosine kinase inhibitors (BTKis)</FONT></TD>
    <TD STYLE="text-align: center; border-right: #231F20 1pt solid; border-bottom: #231F20 1pt solid; vertical-align: middle">88</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD ROWSPAN="2" STYLE="border-right: #231F20 1pt solid; border-bottom: #231F20 1pt solid; border-left: #231F20 1pt solid; text-align: center; vertical-align: middle"> Poster Presentation</TD>
    <TD STYLE="text-align: center; border-right: #231F20 1pt solid; border-bottom: #231F20 1pt solid; vertical-align: middle">Lisaftoclax<BR>
 <FONT STYLE="font-family: Times New Roman, Times, Serif">&#65288;</FONT>APG-2575<FONT STYLE="font-family: Times New Roman, Times, Serif">&#65289;</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 2pt; border-right: #231F20 1pt solid; border-bottom: #231F20 1pt solid; padding-left: 5.6pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Results of the APG2575AU101 study of lisaftoclax (APG-2575) combined with azacitidine (AZA) in patients with newly diagnosed (ND) or prior venetoclax&ndash; exposed myeloid malignancies</FONT></TD>
    <TD STYLE="text-align: center; border-right: #231F20 1pt solid; border-bottom: #231F20 1pt solid; vertical-align: middle">1641</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; border-right: #231F20 1pt solid; border-bottom: #231F20 1pt solid; vertical-align: middle">Olverembatinib <FONT STYLE="font-family: Times New Roman, Times, Serif"><BR>
&#65288;</FONT>HQP1351<FONT STYLE="font-family: Times New Roman, Times, Serif">&#65289;</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 2pt; border-right: #231F20 1pt solid; border-bottom: #231F20 1pt solid; padding-left: 5.6pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Results of POLARIS-1, a global phase 3 study (Part A): olverembatinib combined with low-intensity chemotherapy in patients with newly diagnosed (ND) Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL)</FONT></TD>
    <TD STYLE="text-align: center; border-right: #231F20 1pt solid; border-bottom: #231F20 1pt solid; vertical-align: middle">1574</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 2pt; border: #231F20 1pt solid; text-align: center; width: 18%; font-size: 10pt; vertical-align: middle; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt"><B>Format</B></FONT></TD>
    <TD STYLE="padding-top: 2pt; border-top: #231F20 1pt solid; border-right: #231F20 1pt solid; border-bottom: #231F20 1pt solid; vertical-align: middle; width: 21%; font-size: 10pt; text-align: center; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt"><B>Drug Candidate</B></FONT></TD>
    <TD STYLE="padding-right: 5.4pt; border-top: #231F20 1pt solid; border-right: #231F20 1pt solid; border-bottom: #231F20 1pt solid; padding-top: 2pt; text-align: center; width: 45%; font-size: 10pt; vertical-align: middle; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt"><B>Abstract Title</B></FONT></TD>
    <TD STYLE="padding-top: 2pt; border-top: #231F20 1pt solid; border-right: #231F20 1pt solid; border-bottom: #231F20 1pt solid; text-align: center; width: 16%; font-size: 10pt; vertical-align: middle; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt"><B>Abstract<BR> number</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD ROWSPAN="7" STYLE="border-right: #231F20 1pt solid; border-bottom: #231F20 1pt solid; border-left: #231F20 1pt solid; font-size: 10pt">&nbsp;</TD>
    <TD ROWSPAN="6" STYLE="border-right: #231F20 1pt solid; border-bottom: #231F20 1pt solid; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 2pt; border-right: #231F20 1pt solid; border-bottom: #231F20 1pt solid; padding-left: 5.6pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">O l v e r e m b a t i n i b ( H Q P 1 3 5 1 ) demonstrates efficacy vs. best available therapy (BAT) in patients (pts) with t y r o s i n e k i n a s e i n h i b i t o r ( T K I ) - resistant chronic-phase chronic myeloid leukemia (CML-CP) in a registrational randomized phase 2 trial: up to 4-year follow-up including patients without T315I mutations</FONT></TD>
    <TD STYLE="vertical-align: middle; text-align: center; border-right: #231F20 1pt solid; border-bottom: #231F20 1pt solid">3788</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 2pt; border-right: #231F20 1pt solid; border-bottom: #231F20 1pt solid; padding-left: 5.6pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">U p da t ed e ff i c a cy a nd sa f e ty of olverembatinib (HQP1351) as second- line therapy in patients with chronic phase-chronic myeloid leukemia (CP- CML)</FONT></TD>
    <TD STYLE="text-align: center; border-right: #231F20 1pt solid; border-bottom: #231F20 1pt solid; vertical-align: middle">3782</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 2pt; border-right: #231F20 1pt solid; border-bottom: #231F20 1pt solid; padding-left: 5.6pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Preclinical and clinical Study of olverembatinib in patients with myeloid/ lymphoid neoplasms with FGFR 1 rearrangement</FONT></TD>
    <TD STYLE="text-align: center; border-right: #231F20 1pt solid; border-bottom: #231F20 1pt solid; vertical-align: middle">1979</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 2pt; border-right: #231F20 1pt solid; border-bottom: #231F20 1pt solid; padding-left: 5.6pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Olverembatinib-mediated deep remission improves allogeneic stem cell transplantation outcome in patients with blast crisis chronic myeloid leukemia: First real-world practice report</FONT></TD>
    <TD STYLE="text-align: center; border-right: #231F20 1pt solid; border-bottom: #231F20 1pt solid; vertical-align: middle">1999</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 2pt; border-right: #231F20 1pt solid; border-bottom: #231F20 1pt solid; padding-left: 5.6pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">The efficacy and safety of switching to olverembatinib or continuing original TKI therapy in CML-CP patients treated with at least two prior TKIs: A prospective, multicenter, control trial</FONT></TD>
    <TD STYLE="text-align: center; border-right: #231F20 1pt solid; border-bottom: #231F20 1pt solid; vertical-align: middle">3779</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 2pt; border-right: #231F20 1pt solid; border-bottom: #231F20 1pt solid; padding-left: 5.6pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Clinical and molecular features associated with glucolipid metabolic disorders and cardio-/cerebro-vascular adverse events in CML patients receiving olverembatinib therapy</FONT></TD>
    <TD STYLE="text-align: center; border-right: #231F20 1pt solid; border-bottom: #231F20 1pt solid; vertical-align: middle">5561</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; border-right: #231F20 1pt solid; border-bottom: #231F20 1pt solid; vertical-align: middle">APG-5918</TD>
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 2pt; border-right: #231F20 1pt solid; border-bottom: #231F20 1pt solid; padding-left: 5.6pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Embryonic ectoderm development (EED) inhibitor APG-5918 overcomes immunomodulatory drug (IMiD) resistance as monotherapy and synergizes with IMiDs/cereblon E3 ligase modulators (CELMoDs) in preclinical models of multiple myeloma (MM)</FONT></TD>
    <TD STYLE="text-align: center; border-right: #231F20 1pt solid; border-bottom: #231F20 1pt solid; vertical-align: middle">1528</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 2pt; text-align: center; border: #231F20 1pt solid; width: 18%; font-size: 10pt; vertical-align: middle; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt"><B>Format</B></FONT></TD>
    <TD STYLE="padding-top: 2pt; text-align: center; border-top: #231F20 1pt solid; border-right: #231F20 1pt solid; border-bottom: #231F20 1pt solid; width: 21%; font-size: 10pt; vertical-align: middle; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt"><B>Drug Candidate</B></FONT></TD>
    <TD STYLE="padding-right: 5.4pt; border-top: #231F20 1pt solid; border-right: #231F20 1pt solid; border-bottom: #231F20 1pt solid; padding-top: 2pt; text-align: center; width: 45%; font-size: 10pt; vertical-align: middle; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt"><B>Abstract Title</B></FONT></TD>
    <TD STYLE="padding-top: 2pt; text-align: center; border-top: #231F20 1pt solid; border-right: #231F20 1pt solid; border-bottom: #231F20 1pt solid; width: 16%; font-size: 10pt; vertical-align: middle; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt"><B>Abstract <BR>
number</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD ROWSPAN="2" STYLE="border-right: #231F20 1pt solid; border-bottom: #231F20 1pt solid; border-left: #231F20 1pt solid; text-align: center; vertical-align: middle">Abstract Only</TD>
    <TD STYLE="text-align: center; border-right: #231F20 1pt solid; border-bottom: #231F20 1pt solid; vertical-align: middle">Olverembatinib <FONT STYLE="font-family: Times New Roman, Times, Serif">&#65288;</FONT>HQP1351<FONT STYLE="font-family: Times New Roman, Times, Serif">&#65289;</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 2pt; border-right: #231F20 1pt solid; border-bottom: #231F20 1pt solid; padding-left: 5.6pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Single CAR-t infusion during front-line consolidation induces deep and sustained remission in newly diagnosed adult ph+b- ALL: A prospective phase 2 study</FONT></TD>
    <TD STYLE="text-align: center; border-right: #231F20 1pt solid; border-bottom: #231F20 1pt solid; vertical-align: middle">442</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; border-right: #231F20 1pt solid; border-bottom: #231F20 1pt solid; vertical-align: middle">Lisaftoclax <FONT STYLE="font-family: Times New Roman, Times, Serif">&#65288;</FONT>APG-2575<FONT STYLE="font-family: Times New Roman, Times, Serif">&#65289;</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 2pt; border-right: #231F20 1pt solid; border-bottom: #231F20 1pt solid; padding-left: 5.6pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">B C L - 2 i n h i b i t i o n i n N o r t h American adult T-cell leukemia/ lymphoma: Preclinical insights and early clinical outcomes</FONT></TD>
    <TD STYLE="text-align: center; border-right: #231F20 1pt solid; border-bottom: #231F20 1pt solid; vertical-align: middle">3304</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">Major study abstracts on olverembatinib and lisaftoclax selected
for presentations at the 2025 ASH Annual Meeting are as follows:</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B><U>Oral Presentation</U></B></P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt; text-align: left">Results of a registrational phase
2 study of lisaftoclax monotherapy for treatment of patients (pts) with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic
lymphoma (CLL/SLL) who had failed Bruton&rsquo;s tyrosine kinase inhibitors (BTKis)</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B>&nbsp;</B></P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B>Format:</B> Oral Presentation</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="text-indent: 0pt; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt">Abstract number: <FONT STYLE="font-weight: normal">88</FONT></P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt; text-align: left"><B>Session: </B>642. Chronic Lymphocytic
Leukemia: Clinical and Epidemiological: Treatment of CLL in Relapse and in Richter Transformation</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="text-indent: 0pt; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt">Time:</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B>&nbsp;</B></P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">Saturday, December 6, 2025; 10:15 AM &ndash; 10:30 AM (US
Eastern Standard Time)</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">Saturday, December 6, 2025; 11:15 PM &ndash; 11:30 PM (Beijing
Time)</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt; text-align: left"><B>First Author: </B>Prof. Keshu Zhou,
The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt; text-align: left"><B>Presenter:</B> Prof. Keshu Zhou,
The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="text-indent: 0pt; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt">Highlights:</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt; text-align: left">This is a pivotal registrational Phase
II study (NCT05147467) in patients with CLL/SLL, with the objective response rate (ORR) as its primary endpoint. Patients in this study
were refractory to, relapsed on, or intolerant of both BTK inhibitors and immunochemotherapy; or failed prior BTK inhibitors and were
ineligible for immunochemotherapy.</P>




<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt; text-align: left"><B><U>Efficacy Results</U></B>: As of
July 25, 2025, among 72 evaluable patients with R/R CLL/SLL, the ORR as confirmed by the independent review committee (IRC) was 62.5%,
the median progression-free survival (mPFS) was 23.89 months (with a median follow-up of 22.01 months). Among high-risk patients (those
with adverse prognostic genotypes such as del(17p)/<FONT STYLE="font-size: 10pt"><I>TP53 </I></FONT>mutation, chromosomal complex karyotype,
and unmutated <FONT STYLE="font-size: 10pt"><I>IGHV</I></FONT> ), the treatment showed clinically meaningful deep responses. 21.8% of
patients achieved minimal residual disease (MRD) negativity in peripheral blood. In the 11 evaluable patients with bone marrow MRD, 6
achieved MRD-negativity.</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt; text-align: left"><B><U>Safety Results</U></B>: Lisaftoclax
demonstrated a manageable safety profile in BTKi-pretreated patients. Frequent grade &ge;3 treatment-related adverse events were hematologic
toxicities that included decreased neutrophil, decreased platelet count, and anemia. No tumor-lysis syndrome (TLS) was reported and no
treatment-related deaths occurred during the study.</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt"><B><U>Conclusion</U>:</B>
Lisaftoclax monotherapy demonstrated significant and durable clinical efficacy and a manageable safety profile in patients with heavily-pretreated
BTK-refractory R/R CLL/SLL, underscoring its utility as a potential new treatment option.</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><B><U>Poster Presentation:</U></B></P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt; text-align: left">Results of the APG2575AU101 study
of lisaftoclax (APG-2575) combined with azacitidine (AZA) in patients with newly diagnosed (ND) or prior venetoclax-exposed myeloid malignancies</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B>&nbsp;</B></P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B>Format:</B> Poster Presentation</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="text-indent: 0pt; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt">Abstract number: <FONT STYLE="font-weight: normal">1641</FONT></P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B>Session:</B> 616. Acute Myeloid Leukemias: Investigational
Drug and Cellular Therapies: Poster I</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="text-indent: 0pt; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt">Time:</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B>&nbsp;</B></P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">Saturday, December 6, 2025; 5:30 PM &ndash; 7:30 PM (US Eastern
Standard Time)</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">Sunday, December 7, 2025; 6:30 AM &ndash; 8:30 AM (Beijing
Time)</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><B>First Author: </B>Dr. Tapan Kadia,
Department of Leukemia, The University of Texas MD Anderson Cancer Center</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><B>Presenter:</B> Dr. Tapan Kadia, Department
of Leukemia, The University of Texas MD Anderson Cancer Center</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="text-indent: 0pt; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt">Highlights:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>This is a phase I/II study (NCT04964518) designed to evaluate the safe dose and efficacy of lisaftoclax in combination with AZA in
patients with ND or R/R acute myeloid leukemia (AML), mixed-phenotype acute leukemia (MPAL), chronic myelomonocytic leukemia (CMML), or
higher-risk (HR) myelodysplastic syndromes (MDS). The first part of this study is the dose-escalation phase and the second part is the
dose-expansion phase.</TD></TR></TABLE>




<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>As of July 1, 2025, a total 103 patients were enrolled, including 63 patients with AML/MPAL (of whom 56 patients had relapsed/refractory
diseases) and 40 patients with HR MDS/CMML (of whom 25 patients had relapsed/refractory diseases).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B><U>Efficacy Results as of July 1, 2025</U></B>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: left">In the 47 evaluable patients with R/R AML/MPAL, the ORR was 40.4%, the complete response (CR) rate was 29.8% (14/47). In the 24 patients
with venetoclax-exposed R/R AML/ MPAL, the ORR was 29.2% (7/24), the CR rate was 20.8% (5/24).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: left">In the 15 evaluable patients with ND HR MDS/CMML, the ORR was 80.0%, including 6 (40.0%) patients who achieved a CR, and 6 (40.0%)
who achieved a marrow CR (mCR).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: left">Median overall survival (OS) values for patients with R/R AML/MPAL or R/R HR MDS/ CMML were 7.6 months and 11.3 months, respectively.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>The median OS of patients with ND AML/MPAL was 6.3 months and it was not reached in patients with ND HR MDS/CMML.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt"><B><U>Safety Results</U>:</B>
No dose-limiting toxicities (DLTs) were reported in part one for dose-escalation or part two for dose-expansion. Common grade &ge;3 treatment-emergent
adverse events (TEAEs) included neutropenia (41.7%), febrile neutropenia (35.0%), thrombocytopenia (26.2%), anemia</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">(17.5%).</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt; text-align: left"><B><U>Conclusion</U>:</B> These preliminary
clinical data show that the combination regimen of lisaftoclax plus AZA holds promise in overcoming venetoclax resistance, therefore potentially
offering a new treatment option to patients with AML/HR MDS.</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt; text-align: left">Results of POLARIS-1, a global
Phase 3 study (Part A): olverembatinib combined with low-intensity chemotherapy in patients with newly diagnosed (ND) Philadelphia chromosome-positive
(Ph+) acute lymphoblastic leukemia (ALL)</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B>&nbsp;</B></P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B>Format:</B> Poster Presentation</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="text-indent: 0pt; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt">Abstract number: <FONT STYLE="font-weight: normal">1574</FONT></P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><B>Session:</B> 613. Acute Lymphoblastic
Leukemias: Therapies Excluding Allogeneic Transplantation: Poster I</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="text-indent: 0pt; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt">Time:</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B>&nbsp;</B></P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">Saturday, December 6, 2025; 5:30 PM &ndash; 7:30 PM (US Eastern
Time)</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">Saturday, December 7, 2025; 6:30 AM &ndash; 8:30 AM (Beijing
Time)</P>




<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt; text-align: left"><B>First Author:</B> Prof. Suning Chen,
Department of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt; text-align: left"><B>Presenter:</B> Prof. Suning Chen,
Department of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="text-indent: 0pt; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt">Highlights:</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt; text-align: left">This is a global registrational Phase
III study (POLARIS-1; NCT06051409) designed to evaluate the efficacy and safety of olverembatinib combined with low-intensity chemotherapy
in patients with ND Ph<SUP>+</SUP> ALL. The primary endpoint of the study was minimal residual disease (MRD; BCR-ABL/ABL1 &le; 0.01% by
qPCR) negativity rate by the end of three induction cycles.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B><U>Efficacy Results</U>:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: left">As of July 18, 2025, among 53 efficacy-evaluable patients, 50 (94.3%) achieved a complete remission (CR) or CR with incomplete hematologic
recovery by the end of induction therapy. The best MRD negativity and MRD-negative CR rates were 66.0% and 64.2%, respectively.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: left">IKZF<SUP>1</SUP>plus (particularly
                                            with concurrent BTG1 deletion) is a widely recognized high-risk factor in B-ALL as it can
                                            often cause resistance to chemotherapies and a high propensity to relapse. Among the 10 patients
                                            in this study who had this genotype, the molecular response rate at the end of the induction
                                            therapy was 90% (9/10).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><B><U>Safety Results</U>: </B>Olverembatinib
in combination with low-dose chemotherapy was well tolerated. Common (incidence &gt;15%) grade &ge;3 treatment-emergent adverse events
(TEAEs) were neutropenia (63.6%), thrombocytopenia (56.4%), leukopenia (54.5%), anemia (49.1%), pneumonia (30.9%), hypokalemia (20%),
and abnormal hepatic function (16.4%).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B><U>Conclusion</U>:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: left">In patients with ND Ph+ ALL, olverembatinib in combination with chemotherapy demonstrated an MRD-negative CR rate of 64.2% by the
end of the induction therapy and a favorable safety profile.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt; text-align: left">Olverembatinib (HQP1351) demonstrates
efficacy vs. best available therapy (BAT) in patients (pts) with tyrosine kinase inhibitor (TKI)-resistant chronic-phase chronic myeloid
leukemia (CML-CP) in a registrational randomized phase 2 trial: up to 4-year follow-up including patients without T315I mutations</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B>&nbsp;</B></P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B>Format:</B> Poster Presentation</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="text-indent: 0pt; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt">Abstract number: <FONT STYLE="font-weight: normal">3788</FONT></P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B>Session:</B> 632. Chronic Myeloid Leukemia: Clinical and
Epidemiological: Poster II</P>




<P STYLE="text-indent: 0pt; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="text-indent: 0pt; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt">Time:</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B>&nbsp;</B></P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">Sunday, December 7, 2025; 06:00 PM - 08:00 PM (US Eastern
Time)</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">Monday, December 8, 2025; 07:00 AM - 09:00 AM (Beijing Time)</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><B>First Author:</B> Prof. Qian Jiang, Peking University
Institute of Hematology, Peking University People&rsquo;s Hospital, Beijing, China</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><B>Presenter:</B> Prof. Qian Jiang, Peking University Institute
of Hematology, Peking University People&rsquo;s Hospital, Beijing, China</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="text-indent: 0pt; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt">Highlights:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: left">This is an open-label, randomized controlled, multicenter, pivotal registrational phase II study (NCT04126681) designed to evaluate
the efficacy and safety of olverembatinib in patients with CML-CP resistant and/or intolerant to first &ndash; and second-generation TKIs.
This report features an update on the results released in an oral presentation at ASH 2023. As of January 13, 2025, a total of 144 patients
with CML-CP were enrolled in the study, including 105 patients without the T315I mutation.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: left">In this study, patients were randomized at a 2:1 ratio to the olverembatinib arm or the control arm with investigators&rsquo; choices
of best available treatment (BAT). The primary endpoint is event-free survival (EFS).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B><U>Efficacy Results</U>:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>The olverembatinib arm achieved a significantly longer EFS than the BAT arm: among all patients with CML-CP, the median EFS of the
olverembatinib arm and the BAT arm were 21.22 months
and 2.86 months (<FONT STYLE="font-size: 10pt"><I>P</I></FONT> &lt; 0.001), respectively. Among patients with CML-CP without the T315I
mutation, the median EFS of the olverembatinib arm and the BAT arm were 11.96 months and 3.14 months (<FONT STYLE="font-size: 10pt"><I>P</I></FONT>
= 0.0159), respectively.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34.85pt; text-align: justify; text-indent: -0.05pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>Other efficacy parameters of the olverembatinib arm were significantly better than those of the BAT arm: among all patients with CML-CP,
complete hematologic response (CHR) rates of the olverembatinib arm and the BAT arm were 85% and 34.8%; the complete cytogenetic response
(CCyR) rates were 37.5% and 18.9%; the major molecular response (MMR) rates were 29.5% and 8.1%, respectively. Among patients with CML-CP
without the T315I mutation treated in the olverembatinib arm or the BAT arm, the CHR rates were 82.1% and 50.0%, the CCyR rates were 25.8%
and 20.7%, the MMR rates were 16.1% and 10.3%, respectively.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><B><U>Safety Results</U></B>: Both
olverembatinib and BAT showed a favorable safety profile in patients with CML-CP with/without the T315I mutation. Major adverse event
were hematologic toxicities.</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B><U>Conclusion</U></B>: Olverembatinib demonstrated clear
therapeutic advantage over the BAT arm in patients with CML-CP resistant and/or intolerant to first &ndash; and second-generation TKIs.</P>




<P STYLE="text-indent: 0pt; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt; text-align: left">Updated efficacy and safety of
olverembatinib (HQP1351) as second-line therapy in patients with chronic phase-chronic myeloid leukemia (CP-CML)</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B>&nbsp;</B></P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B>Format:</B> Poster Presentation</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="text-indent: 0pt; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt">Abstract number: <FONT STYLE="font-weight: normal">3782</FONT></P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B>Session:</B> 632. Chronic Myeloid Leukemia: Clinical and
Epidemiological: Poster II</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="text-indent: 0pt; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt">Time:</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B>&nbsp;</B></P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">Sunday, December 7, 2025; 6:00 PM &ndash; 8:00 PM (US Eastern
Standard Time)</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">Monday, December 8, 2025; 7:00 AM &ndash; 9:00 AM (Beijing
Time)</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt; text-align: left"><B>First Author:</B> Prof. Weiming Li,
Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt; text-align: left"><B>Presenter:</B> Prof. Weiming Li,
Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="text-indent: 0pt; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt">Highlights:</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt; text-align: left">This is an open-label, single-arm, multicenter
clinical study (ChiCTR2200061655) designed to evaluate the efficacy and safety of orally administered olverembatinib at 40 mg every other
day (QOD) in patients with CP-CML resistant/intolerant to one prior line of TKIs (including imatinib, flumatinib, nilotinib, and dasatinib)
without the T315I mutation. As of July 24, 2025, the study has enrolled a total of 47 patients with CP-CML without the T315I mutation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B><U>Efficacy Results</U>:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>As of July 24, 2025, 39 (83.0%) patients received at least one efficacy evaluation; 36 (76.6%) at least two efficacy evaluations;
and 34 (72.3%) at least three efficacy evaluations. Two patients had not yet received their first efficacy evaluation.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: left">As of the data cut-off date, 71.8% (28/39) of patients achieved a CCyR and 43.6% (17/39) MMR. CCyR and MMR rates assessed at the end
of cycles 6, 9, 12, 15, 18, 21, and 24 were 54.3% and 25.7%, 66.7% and 33.3%, 74.2% and 35.5%,
84.6% and 46.2%, 85.7% and 47.6%, 90.0% and 60.0%, and 89.5% and 57.9%, respectively, suggesting that responses deepened as
treatment persisted.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34.85pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>Among 39 efficacy-evaluable patients, 30 had received second-generation TKIs in first-line treatment. Of them, 76.7% (23/30) achieved
a CCyR and 43.3% (13/30) MMR. Among the 9 patients who were pretreated with imatinib, 55.6% (5/9) achieved a CCyR and 44.4% (4/9) MMR.</TD></TR></TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt; text-align: left"><B><U>Safety Results</U>:</B> The median
(range) treatment duration was 16.0 (1-18) cycles. A total of 42 (89.4%) patients experienced treatment-related adverse events (TRAEs)
of any grade, including 21 (44.7%) patients who experienced grade &ge;3 TRAEs and 6 (12.8%) patients who experienced serious adverse events
(SAEs) related to olverembatinib. Grade&ge;3 hematologic toxicities included platelet count decreased (42.6%), neutropenia (25.5%), and
anemia (8.5%). Olverembatinib-related SAEs included platelet count decreased (6.4%) and anemia, myelosuppression, and pyrexia (2.1% each).
No deaths were reported during the study.</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt; text-align: left"><B><U>Conclusion</U>:</B> Olverembatinib
may provide a safe and effective second-line treatment for patients with CP-CML, especially for those with disease that had failed on
first-line treatment with second-generation TKIs.</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt; text-align: left"><B>Cautionary Statement required by
Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited:</B> We cannot guarantee that
we will be able to obtain further approval for, or ultimately market APG-5918 successfully.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 283.75pt; text-align: center">By order of the Board</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 294pt; text-align: center"><B>Ascentage Pharma Group International</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 294pt; text-align: center"><B>Dr. Yang Dajun</B></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 294pt; text-align: center">Chairman and Executive Director</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6.5pt">&nbsp;</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">Suzhou, People&rsquo;s Republic of China, November 4, 2025</P>

<P STYLE="text-indent: 0pt; font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt; text-align: left">As at the date of this announcement,
the Board of Directors of the Company comprises Dr. Yang Dajun as Chairman and executive Director, Dr. Wang Shaomeng and Dr. Lu Simon
Dazhong as non-executive Directors<FONT STYLE="font-size: 10pt"><SUP>Note</SUP></FONT>, and Mr. Ye Changqing, Mr. Ren Wei and Dr. David
Sidransky and Ms. Marina S. Bozilenko and Dr. Debra Yu and Marc E. Lippman, MD as independent non-executive Directors.</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><I>Note: Dr. Wang Shaomeng and Dr.
Lu Simon Dazhong are independent directors under NASDAQ rules.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"><I></I></P>

<!-- Field: Page; Sequence: 9; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"><I>&nbsp;</I></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  X *,# 2(  A$! Q$!_\0
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M/\+Y+#5_&D-FWFQW'Q-\90PQZ58SK&X65_"_ABYCN9(9UQ!<:V[JZ-')C?\
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MVDK>']/6UA>$WMXLOYY_$OP]^RI\&_AAX&^*O[,G[=GQ(\7_ +4FBZEX;O\
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M%\7>$[Z[1(KNYT#7($D:W%W'%$EW97D%YIM[Y4+75G*\$#1_ECX9_P"#=/\
M8CT7Q!!JVL>*_C5XGTJ&Y,[>';SQ/HFF6UZHDWI:ZAJ.D>';74I+9E!CG%I<
M64THY2>%N:**^QR+Q&X\X9RV>4Y!Q;GF4Y;5E4F\#@\;*&'ISJN3JSH0J4J[
MPTZC7-4GA9X:4Y>_+W_??PV>^&O /%&91S?B'A'(\VS.G&E!XW%X/FQ%6%&R
MHPQ,J5;#K%PI)*,(8N&)C&/N+W/<7[>?#/X9^!/@[X(\.?#7X9^%M(\&>!O"
M6G1Z7X>\.:);BWL-.M$)=@H)::>XGE>2XO+RYDFN[RYEENKJ:6>9W;O:**^1
MJUJV(K5L1B*M6O7KU:E:M7K5)U:U:K5G*I4JU:M2<ZE2I4G*4YSG.4YRE*4I
M.4FW]I0H4<+1I8;#4:6'P^'ITZ%"A0IPHT:-&E"$*5*E2IPA3ITZ<(QA"$(1
.A&,5&,4E8****@U/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>ex99-2_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-2_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  W *,# 2(  A$! Q$!_\0
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M-H_B&[@\9Z#KL.OVOB73=(@N!H^N:3K5Y'+)XBT?1I)%M)+@+'$;:-O+^?\
M]L+X&?\ !6+_ (*%CX<_&WXH?LK:=\/]/^%NNZ)X0\-?"_P\38>,[V'Q!JD-
MYXD\9S:7KFL7VJ'0[&73=/CNY+R]LXK6">.6PL[I8K^>/^R+:HZ #G/X\_XF
M@J#U'^?KUI9-XZ9WDV&R.G2X7X1Q&,X:><T,AS+$83,OK&4Y5GV)QN)Q^3X.
MC1S*EA88>^.J8?#8JI2K8W#X6%.E&<G%U)/.O +(\[Q6>5:W%?&&&P7$L,DK
M9_EM#%Y;*AFV;9!AL)ALOSC&5ZV6U,5/$?[)'$XC#4ZM#!U\75JUG""<:</X
MK/\ @I-XI7X\_P#!2/1?V8_VM?C%>_L\?L[?"3PQH>C>%_$+>&FUS3M!DU+X
M?Z9J=QXD,4*1M<2>-=?CCTV;Q!---INFZ?96ENR$6FZO0?V9_P!C_P#X)(>&
M?BYX+\1?%?\ X*0^%/V@T\/:EI">#?A_K,+^"O"EQ<V-R)=*TS7[W5+[63<:
M%#>^3(FBV]]HFESL'BN_.MI'B.;_ ,%L?&VDZ]_P4I^#_@']I'1-4\/?LS^#
MM%\!W-QK_@[1;2/QIXH\%>)&6\\=ZK8ZV]L+W4VTO5X9] BTY;J6'2K?3KJX
ML+>+4+^1YOG#_@I!H_\ P2"T?X0>$D_87U;5-5^,$_B*PDU"31]5\=ZKX9B\
M'&VN/[;B\8_\)T&2'5_.^Q'1UT8),9_M7VMFME"5_2W#]#'YKP?X6\/X',./
MN%\-Q7PE#"S? F39%F?#& J5*F84\7FV<9YB<$LPRS,<SBY8C-:5#&4JU"-7
MV?MYU>90_EWB"M@,HXR\5.(,?E_A_P 4XKA/C"6)A'CW.,^RSB?,:5..7RP>
M5Y3D6$QG]GYG@,L<(8?*ZE;"5*5=T8U%0A2E&,OVN_X*X_\ !.#XK_M#^+/A
MI^V%^R#J%O-\;?AQI>APRZ-I6K6FF7_B32/#M^_B+P3XI\$ZW+.NG-KWARYF
MF-G9M/#!JMC<0&TE:XB6.;YK^%7QA_X."_B[\2/AAX>U;X<)\.- \+>)M'U+
MQ?KOC?P%X<\"^%_$6D6$Z6^K6OBW4A-=:AJ5K=V$\[G3/"EO#=7%XL-Q:J'@
M0K^MG_!(32OB?I/_  3V_9XL_BQ_:J:Z?#VJ76A6NNBX&LV7@>ZUW4)O!UM?
MBZ5;D*-%>"734G+M'H\VG1(5B2.-/TMP#C(SCUK^:L9XCX[AG#XS@',\AX)X
M[H\(8S/>'^'.(<^RJKC<7E^!^N8[#5%@I4<92HU\,YRJ8C"TL3.M'"UI/V=6
MHJ%&JOZAP/AE@.*<1@O$+*N(.-^ :W&6#R+B#B7AW(,UI8+"9CCOJF"Q--XV
M-7"5*M#$J$:='$5<-&F\30Y7.E3E7KT7'!YWD0_:!&+@QH9Q"6:$3%091"7
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&BBBF,__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>ex99-3_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-3_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !0 /T# 2(  A$! Q$!_\0
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M4S#!8GVL:7M:U1UJ\J,X8;&4:E&=>4\3"AB,*JF&KU*KP]=0J<J_!3_@G/\
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A%:IB<3.G"3<H4O:U7"C&3<U2IP<_?G-1****^8/I3__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
